Physician Dispensing and Community Oncology: Legal Considerations for Practices Operating In-House Pharmacies

By Ron Lanton III, Esq. | Lanton, Lanton & Sosa Law PLLC

For community oncology practices, providing oral cancer medications directly to patients can improve coordination between physicians, pharmacists, and clinical staff. It can also allow practices to monitor treatment more closely and address medication-related problems without relying entirely on outside specialty pharmacies.

However, establishing or expanding an in-house dispensing operation involves legal and financial decisions that extend beyond patient care.

Practices must determine whether their dispensing arrangements comply with federal and state requirements, whether they can participate in the necessary payer networks, and whether reimbursement will support the cost of operating the service.

These issues should be evaluated before a practice invests in additional pharmacy personnel, technology, inventory, or facilities.

Physician Dispensing and Regulatory Requirements

The legal structure of an oncology dispensing operation depends partly on state law.

Some states permit physicians to dispense medications under specified conditions. Other arrangements may require a separately licensed pharmacy, additional permits, or compliance with requirements imposed by both medical and pharmacy boards.

The distinction affects ownership, supervision, staffing, recordkeeping, and the ability to dispense medications to patients.

Federal physician self-referral requirements also need attention. The Stark Law generally restricts certain Medicare referrals involving entities with which physicians have financial relationships. The in-office ancillary services exception may permit qualifying dispensing arrangements, but practices must satisfy its applicable conditions.

Those conditions can include requirements concerning the location of services, supervision, group practice structure, and billing.

Practices dispensing oral oncology medications should also examine how medications are delivered to patients. Mailing or delivering prescriptions outside the office can create additional compliance concerns when an arrangement depends on the in-office ancillary services exception.

The federal Anti-Kickback Statute and applicable state laws may create further obligations, particularly when dispensing operations involve management companies, compensation arrangements, or outside business partners.

PBM Networks and Reimbursement

Regulatory permission to dispense medication does not guarantee that a practice will receive reimbursement for doing so.

Community oncology practices may encounter PBM network restrictions, specialty pharmacy requirements, limited distribution arrangements, and payer policies directing prescriptions to outside pharmacies.

These restrictions can affect whether an in-house dispensing operation is financially sustainable.

Practices should examine applicable PBM agreements, network eligibility requirements, reimbursement terms, and audit provisions before expanding services. They should also determine whether payer arrangements permit the proposed dispensing model.

Reimbursement for oral oncology medications may differ from reimbursement for physician-administered drugs. Coverage under Medicare Part B, Part D, Medicaid, or commercial insurance depends on the medication and applicable benefit rules.

Management should understand the expected payment structure, acquisition costs, working capital requirements, and potential reimbursement delays before making financial commitments.

A dispensing operation that improves care coordination may still create financial difficulties if reimbursement does not adequately support its operating expenses.

Evaluating an In-House Pharmacy Arrangement

Before establishing or expanding dispensing services, oncology practices should review their existing corporate structure, physician compensation arrangements, pharmacy licensing requirements, payer contracts, and operational responsibilities.

If the arrangement involves a management services organization, outside pharmacy partner, or separate legal entity, the agreements should clearly address ownership, management authority, compensation, compliance obligations, and responsibility for pharmacy operations.

Practices should also consider how patients will receive medications, how pharmacists and clinical staff will communicate, and what happens when an insurer requires a prescription to be filled elsewhere.

These decisions affect patient care, legal compliance, and the financial performance of the practice.

In-house dispensing can be an important service for community oncology patients. Its benefits, however, depend on having an operating model that complies with applicable law and can function under the practice's payer arrangements.

Before expanding dispensing services, oncology executives should determine whether the proposed structure is legally permissible, commercially workable, and capable of supporting the patients it is intended to serve.

This article is for general informational purposes and does not constitute legal advice.

Next
Next

Buying an Independent Pharmacy: Legal Issues That Can Affect the Transaction